These 3 Biotech Stocks Can Triple from Current Levels, Say Five-Star Analysts – 12/19/2025

If you're looking for investment ideas right now, several top-rated Wall Street analysts (each with five-star ratings) believe that the following stocks are Buys with room to grow from current levels. These picks are considered to have solid upside potential based on their research. You can click on any ticker below to explore the company in depth and decide whether it deserves a spot in your portfolio.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential AnaptysBio (ANAB) Stock – AnaptysBio is a clinical-stage biotechnology company that engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Analyst Yatin Suneja from Guggenheim increased his price target from $100-$140 per share. This equates to an upside of more than 194% from current levels. LB Pharmaceuticals (LBRX) Stock – LB Pharmaceuticals is a clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases. Analyst Yasmeen Rahimi from Piper Sandler reiterated her Buy rating on the stock and maintained a price target of $78 per share. This equates to an upside of more than 295% from current levels. Viking Therapeutics (VKTX) Stock – Viking Therapeutics is a biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Analyst Joseph Pantginis from H.C. Wainwright reiterated his Buy rating on the stock and maintained a price target of $102 per share. This equates to an upside of more than 200% from current levels. To see the full list of recently rated stocks, visit TipRanks' Daily Stock Ratings & Price Targets tool.